We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ACADIA Pharmaceuticals Inc (ACAD)
An SI Board Since April 2004
Posts SubjectMarks Bans Symbol
588 34 0 ACAD
Emcee:  michael_f_murphy Type:  Unmoderated

We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently have five drug programs in clinical and preclinical development. Our three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease currently in Phase II clinical trials, and ACP-104 and ACP-103, both for the treatment of schizophrenia and expected to enter into Phase II clinical trials in 2004. We have retained worldwide commercialization rights to these drug candidates. We also have two preclinical programs for the development of drug candidates for neuropathic pain and glaucoma in collaboration with Allergan, Inc. Using our proprietary drug discovery platform, we have discovered all of the drug candidates in our product pipeline.

The annual worldwide market for drugs used to treat Parkinson’s disease exceeds $2 billion, and the annual worldwide market for drugs used to treat schizophrenia and other psychoses exceeds $12 billion. Current therapies in each of these two markets have substantial limitations, and we believe that significant opportunities exist for improved therapies.

We leverage our proprietary drug discovery platform and expertise through collaborations with leading pharmaceutical and biotechnology companies. We have three collaborations with Allergan and one with Amgen for the discovery of small molecule drug candidates and a technology license agreement with Aventis.

We have assembled a management team with significant industry experience to lead the discovery, development and commercialization of our drug programs. We complement our management team with a network of scientific and clinical advisors that includes recognized experts in the fields of Parkinson’s disease, schizophrenia and other central nervous system disorders.

Our Clinical and Preclinical Development Programs

In our first clinical program, we discovered and are developing ACP-103, a small molecule drug candidate, to treat the debilitating psychiatric and neurological dysfunction produced by current Parkinson’s disease therapies. ACP-103 is given orally and blocks the activity of a serotonin receptor that plays an important role in the treatment of various neuropsychiatric disorders. We are currently conducting our second Phase II clinical trial with ACP-103. This trial is designed to evaluate the efficacy and safety of this drug candidate in Parkinson’s disease patients suffering from treatment-induced hallucinosis or psychosis without impairing motor skills.

In February 2004, we completed the treatment phase of a Phase Ib/IIa clinical trial designed to evaluate the safety and tolerability of ACP-103 in Parkinson’s disease patients. In 2003, we completed two Phase I clinical trials that assessed the safety, tolerability and blood drug levels of ACP-103. In all of our clinical trials to date, ACP-103 has been well tolerated and no serious adverse events have been observed.

In our second clinical program, we are developing ACP-104, a small molecule drug candidate, as a novel therapy for schizophrenia with the added advantage of beneficial cognitive effects. We plan to conduct four Phase II clinical trials with ACP-104 in 2004. The first two clinical trials will focus on safety and tolerability,and the second two clinical trials are designed to assess the efficacy of ACP-104 in the treatment of patients with schizophrenia having acute psychosis or untreated cognitive disturbances. ACP-104 acts upon a set of targets that have been validated by clinical experience to provide antipsychotic activity and cognitive enhancement.

In our third clinical program, we discovered and are developing ACP-103 as an adjunctive therapy to be used with current antipsychotic treatments. We plan to initiate a Phase II clinical trial with ACP-103 in mid-2004 to evaluate its ability, in combination with an antipsychotic drug, to reduce acute exacerbations of schizophrenia. We believe that the use of ACP-103 will result in an improved antipsychotic therapy without the severe, dose-limiting side effects of existing drugs.

In addition to our clinical programs, we have two programs in preclinical development in collaboration with Allergan. In the first program, we have discovered a new class of compounds that we believe represents a significant breakthrough in the treatment of neuropathic pain. Allergan has announced that it intends to initiate Phase I clinical trials for two compounds in 2004 and begin Phase II clinical trials in this program in 2005. In the second program, we have discovered, and in collaboration with Allergan, are developing AC-262271, a small molecule drug candidate for the treatment of glaucoma. AC-262271 has been found to have a promising preclinical profile and has been selected for testing for lowering intraocular pressure in humans.

Our Drug Discovery Platform

We have built a proprietary drug discovery platform that we use to rapidly discover new compounds that may serve as potential treatments for significant unmet medical needs. Our platform encompasses proprietary target-based and chemistry-based technologies that we integrate with our discovery and development capabilities. We believe that the breadth of our discovery and development programs and the rapid pace at which we have discovered drug candidates provide strong validation of our proprietary platform and a basis for expanding our pipeline.

We have established drug discovery and technical expertise in the areas of molecular biology, ultra-high throughput screening, molecular and behavioral pharmacology, and combinatorial, medicinal and analytical chemistry. In addition, we collaborate with world-renowned scientists, clinicians and academic institutions. We believe that our expertise, combined with our proprietary drug discovery platform, has allowed us to discover drug candidates more efficiently than traditional approaches.

Our Strategy

Our goal is to become a leader in the discovery, development and commercialization of novel small molecule drugs for the treatment of central nervous system disorders and other areas of unmet medical need. Key elements of our strategy are to:

• develop and commercialize our lead drug candidates;

• expand our pipeline of drug candidates for the treatment of central nervous system disorders;

• selectively establish strategic collaborations to advance and maximize the commercial potential of our pipeline;

• leverage our proprietary drug discovery platform to identify novel drug candidates outside of our core focus;

• maintain and enhance our technology leadership position; and

• opportunistically in-license or acquire complementary technologies and drug candidates.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
588Company attempts to claim victory in P2 CLARITY trial in MDD: CLARITY PR But ttuck-10/31/2018
587Jan 2019 Options volume 500 at 700 bucks each was $350k for ACAD Jan 18 2019 1singhisking-9/26/2018
586links to the referenced papers,... link.springer.comIan@SI-9/10/2018
585Market News & Research Alert News for ACAD Alert Sent 2018-09-10 09:01:47Ian@SI-9/10/2018
584NowLurking on Ihub commented on this and gave pointer to ACAD IR's response Ian@SI-7/9/2018
583Acadia Pharmaceuticals: This Is Not a Pharmaceuticals Company By Roddy Boyd 2 scion-7/9/2018
582ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Ian@SI-12/20/2016
581ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Ian@SI111/1/2013
580Funny ACAD does not receive very much attention here, as I see trading groups taPatrick Slevin-9/14/2013
579ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Ian@SI-6/18/2013
578Very good group, very professional & knowledgable ....ACAD had some correct2MAR$-6/12/2013
577I'll check out the hub group. Thanks. SI has become lost in more polarized Julius Wong-6/12/2013
576These guys over on the hub keep up regular biotech analysis thread , a pretty k2MAR$-6/12/2013
575Profit taking at the open [graphic]Julius Wong-6/12/2013
574quite the momo until 20 was tested , then sellers finally took over, also AEGR C2MAR$-6/11/2013
573ACAD Charts Message 28938215Julius Wong-6/10/2013
572ACADIA Pharmaceuticals (ACAD) has been selected for addition to the NASDAQ BioteIan@SI15/20/2013
5713 analysts up their targets <pre> Company Ticker Brokerage FirmIan@SI14/11/2013
570Up another 65% today after stating that the PhIII study (top line results reportIan@SI14/11/2013
569Yes, I can understand that. There is a guy on Twitter, Adam Feuerstein, who I uPatrick Slevin-3/25/2013
568unfortunately, not since the Parkinson's failure. I am a sucker for the neumopgcw-3/25/2013
567Thanks for that. Too bad this thread isn't active. Perhaps it shall be if APatrick Slevin-3/25/2013
566Message 28791865Ian@SI-3/24/2013
565Anyone following this stock anymore? My position is from November, and havenPatrick Slevin-3/24/2013
564With 53M shares outstanding, and an estimate of $400M peak sales for Pima in PDPIan@SI111/27/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):